CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2054
Issued: 2026-10-13

PRODUCT IDENTIFICATION

PRODUCT	Semaglutide 15 mg
SKU / INTERNAL CODE	CRF-2026-2054
PRESENTATION	Lyophilised powder, 15 mg vial
BATCH NUMBER	LOT-2610-2054
CLIENT	veltispeptides.mx
SAMPLE RECEIVED	2026-10-08
ANALYSIS DATE	2026-10-11
PRODUCTION DATE	2026-10-06
ISSUED	2026-10-13
EXPIRY / RETEST	2028-10-13

MOLECULAR FORMULA
C187H291N45O59

MOLECULAR WEIGHT	CAS NUMBER
4113.58	910463-68-2

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Thermo Q-Exactive · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C4 2.1×100mm | Temperature: 60°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 0.3 mL/min | Retention time: 12.5 min

CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2054
Issued: 2026-10-13

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.6%	PASS
Quantity	95.0-105.0%	15.1 mg (100.7%)	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Theoretical [M+H]+	4114.6 | Observed: 4114.9 | Δ +0.30 Da	PASS
Sequence Coverage (MS/MS)	≥95% | 98%	PASS
Key fragments	b10 1163.6 · b17 1986.0 · y12 1394.7 · y22 2547.3	PASS
Modifications	acylation intact; deamidation <0.3%	PASS

RESEARCH USE ONLY - NOT FOR HUMAN OR VETERINARY USE

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb		<0.05 µg/g	PASS
As		<0.10 µg/g	PASS
Cd		<0.02 µg/g	PASS
Hg		<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.25 EU/mg | PPC recovery 84%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

GLP-1 agonist. No aggregation detected by SEC (<0.3%).

crafa

CRAFA